User profiles forMitja Jevnikar

MITJA JEVNIKAR

Hopital Bicetre
Verified email at aphp.fr
Cited by 1723

Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial

…, P Durand, P Tissieres,MJevnikar… - JAMA internal …, 2021 - jamanetwork.com
Importance Severe pneumonia with hyperinflammation and elevated interleukin-6 is a common
presentation of coronavirus disease 2019 (COVID-19). Objective To determine whether …

Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension

…, F Picard, P de Groote,MJevnikar2017 -欧盟欧洲……,r Respiratory Soc
Current European guidelines recommend periodic risk assessment for patients with
pulmonary arterial hypertension (PAH). The aim of our study was to determine the association …

Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation

A Beurnier, EM Jutant,MJevnikar… - European …, 2020 - Eur Respiratory Soc
Background Viral respiratory infections are the main causes of asthma exacerbation. The
susceptibility of patients with asthma to develop an exacerbation when they present with …

Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

…, JL Teboul, P Durand, P Tissieres,MJevnikar… - The Lancet Respiratory …, 2021 - Elsevier
Background Patients with COVID-19 pneumonia have an excess of inflammation and
increased concentrations of cytokines including interleukin-1 (IL-1). We aimed to determine …

Prognostic value of follow-up hemodynamic variables after initial management in pulmonary arterial hypertension

…, A Boucly, D Chemla, L Savale, M Peng,MJevnikar… - Circulation, 2018 - Am Heart Assoc
Background: Hemodynamic variables such as cardiac index and right atrial pressure have
consistently been associated with survival in pulmonary arterial hypertension (PAH) at the …

Prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admission

MJevnikar, O Sanchez,R Chocron… - European …, 2021 - Eur Respiratory Soc
Mitja Jevnikar, Olivier Sanchez, Richard Chocron, Marc Andronikof, Maurice Raphael,
Olivier Meyrignac, Laure Fournier, David Montani, Benjamin Planquette, Mary Soudani …

Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension

…, L Savale,X Jaïs,MJevnikar… - European …, 2018 - Eur Respiratory Soc
The prognostic importance of follow-up haemodynamics and the validity of multidimensional
risk assessment are not well established for systemic sclerosis (SSc)-associated pulmonary …

French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension

…,D Fabre, F Parent,MJevnikar… - European …, 2019 - Eur Respiratory Soc
Aims To evaluate safety and efficacy of balloon pulmonary angioplasty (BPA) in a large cohort
of patients with chronic thromboembolic pulmonary hypertension (CTEPH). Methods From …

Portopulmonary hypertension in the current era of pulmonary hypertension management

L Savale, M Guimas, N Ebstein, M Fertin,MJevnikar… - Journal of …, 2020 - Elsevier
Background & Aims Long-term outcomes in portopulmonary hypertension (PoPH) are poorly
studied in the current era of pulmonary hypertension management. We analysed the effect …

Screening for pulmonary arterial hypertension in systemic sclerosis

J Weatherald,D Montani,MJevnikar… - European …, 2019 - Eur Respiratory Soc
Pulmonary arterial hypertension (PAH) is a dreaded complication of systemic sclerosis (SSc)
that occurs in ∼10% of patients. Most individuals present with severe symptoms, significant …